Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: The provided filing covers the three months ended June 30, 2023, Mesa’s fiscal first quarter of fiscal 2024. The request metadata identifies “2022 Q1,” but the filing text clearly reports June 30, 2023, with comparison to June 30, 2022.
Business Context
Mesa is a multinational manufacturer and seller of life science tools and quality-control products and services. Operations are organized into Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Approximately 48% of first-quarter fiscal 2024 revenue was generated outside the United States.
Financial Performance and Position
| Metric | Q1 FY2024 | Q1 FY2023 | Change |
|---|---|---|---|
| Revenue | $50.645 million | $50.453 million | Flat; up approximately 0.4% |
| Gross profit | $31.183 million | $31.341 million | Down 1% |
| Gross margin | 61.6% | 62.1% | Down approximately 0.5 percentage points |
| Operating loss | $0.664 million | $4.594 million | Improved 86% |
| Operating margin | (1.3%) | (9.1%) | Improved |
| Net loss | $0.549 million | $1.438 million | Improved 62% |
| Basic and diluted loss per share | $0.10 | $0.27 | Improved |
| Operating cash flow | $9.939 million | $(2.811) million | Improved $12.750 million |
| Capital expenditures | $0.270 million | $0.225 million | Increased |
Operating expenses declined 11% to $31.847 million, primarily from personnel and other cost-containment measures implemented after the loss of Sema4, a significant Clinical Genomics customer. Interest expense and debt amortization were $1.048 million. A $0.775 million amount of other income, including a payment from a former customer reimbursing prior-period costs, partially offset nonoperating expenses.
Cash and cash equivalents were $32.376 million at June 30, 2023, compared with $32.910 million at March 31, 2023. Working capital was $75.682 million. Total assets were $642.611 million and total stockholders’ equity was $387.719 million.
Debt included $172.5 million principal amount of 1.375% convertible senior notes due August 15, 2025, recorded at a net carrying value of $170.502 million, and $5.0 million outstanding under the credit facility. The credit facility had $75.0 million of revolving capacity, subject to terms and conditions, and a 7.0% borrowing rate at June 30, 2023. Mesa repaid an additional $3.5 million under the facility in July 2023. The company was in compliance with its debt covenants at quarter-end.
Material Changes Versus the Prior Comparable Period
- Consolidated revenue was essentially unchanged, while gross profit declined modestly and gross margin compressed slightly.
- Sterilization and Disinfection Control revenue increased 8% to $15.927 million, benefiting from the abatement of labor shortages and production delays and from price increases.
- Clinical Genomics revenue decreased 8% to $13.369 million, primarily due to the loss of Sema4 and unfavorable currency effects. Gross margin fell to 50% from 54%.
- Biopharmaceutical Development revenue decreased 10% to $9.889 million because of softer demand for capital equipment. Gross margin remained 65%.
- Calibration Solutions revenue increased 12% to $11.460 million as prior production difficulties and supply constraints abated. Gross margin increased to 56% from 55%.
- Operating expenses declined by $4.088 million, allowing the operating loss and net loss to narrow substantially despite relatively flat revenue.
- Operating cash flow improved primarily because of higher collections of receivables and lower bonus payments.
- Foreign currency translation produced a $6.661 million other comprehensive loss, compared with a $15.957 million loss in the prior-year quarter.
Outlook, Risks, Contingencies, and Unusual Items
Management cited persistent high interest rates, inflation, softening demand for discretionary life-science capital equipment, foreign exchange volatility, geopolitical conditions, and potential recessionary conditions. Supply-chain disruptions and labor shortages that affected fiscal 2023 largely abated during the quarter.
Management stated that Biopharmaceutical Development revenue is unlikely to grow at historical levels in fiscal 2024 because of weaker capital-equipment demand. The filing does not provide consolidated revenue, earnings, or cash-flow guidance.
Mesa acquired substantially all assets of Belyntic GmbH’s peptide purification business in November 2022. During the quarter, the company recorded an $0.841 million measurement-period adjustment to goodwill. A $1.5 million contingent cash payment remains payable if specified patents are issued; management believes payment is probable within 36 months. No material legal reserves or impairment charges were recorded.
Disclosure controls were deemed ineffective at June 30, 2023 because a material weakness related to goodwill impairment assessments had not yet been remediated. The material weakness concerning fair-value calculations was considered remediated after Mesa engaged a third-party valuation specialist. Management nevertheless concluded that the reported financial statements fairly present the company’s position and results in conformity with U.S. GAAP.
Mesa declared a quarterly dividend of $0.16 per share payable September 15, 2023. The company also has an unused $150 million equity-sale agreement and had not issued shares under it as of the filing date.
Facts Investors Should Verify
- Confirm the applicable period: the source is a June 30, 2023 Form 10-Q, not a 2022 first-quarter filing.
- Assess whether Clinical Genomics can stabilize following the loss of Sema4 and whether its lower-margin revenue mix persists.
- Monitor Biopharmaceutical Development demand for capital equipment and the expected contribution from consumables and the Belyntic acquisition.
- Evaluate liquidity and refinancing risk before the $172.5 million convertible notes mature in August 2025.
- Track compliance with credit-facility leverage and fixed-charge coverage covenants as interest rates remain elevated.
- Verify remediation of the remaining goodwill impairment internal-control material weakness in subsequent filings.
- Consider the effects of foreign exchange, inflation, customer concentration, and the $1.5 million Belyntic contingent payment.